Cellesce the cancer organoid bioprocessing and scale-up company has announced a successful six-figure funding round that will open up opportunities to introduce its organoid scale-up and expansion technology to the oncology drug discovery screening market. This funding round has, once again, been led by the Development Bank of Wales, a measure of the confidence it has in both the Cellesce technology and the founding team.

Origin Capital and Qi3 Ventures have realised their joint investment in pet health company Lintbells.
Origin and Qi3 backed Lintbells at an early stage of it’s growth in April 2012.

HBAN (Halo Business Angel Network) has invested €300,000 in Kilkenny-based ND Sports Performance and its cloud-based hamstring assessment system products for hamstring injury prevention and improving athlete performance. The funding, which will lead to the creation of up to 10 new jobs, was led by HBAN’s South East Business Angel Network (SEBAN), with support from Enterprise Ireland.

Draper Esprit has co-led in a $12.3 million fund raising by Evonetix, a Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity gene synthesis.

Zilico, part of the Deepbridge Technology Growth EIS portfolio, has secured investment of £13.7 million in its latest funding  round. 

Deepbridge has contributed £3 million of this, with other backers including MaxHealth Medicine Group.

LIfT BioSciences has successfully raised more than £250,000 to develop a pioneering cancer treatment that shares people’s innate immunity to cancer to help potentially cure cancer patients.

A Nottingham regenerative medicine company which has developed a groundbreaking therapy that can help prevent sight loss has completed a £500,000 funding round backed by Mercia Fund Managers, angel investors and the University of Nottingham.

The investment will allow NuVision Biotherapies to further develop its product range, strengthen its management team and increase sales in the UK and internationally.

NanoFlex Limited, an early stage sensor design company, has secured £250,000 of funding from NPIF – Maven Equity Finance, part of the Northern Powerhouse Investment Fund (NPIF).  The fund is delivered by MSIF working with Maven Capital Partners in the Liverpool City Region.

AlzProtect, a biopharmaceutical company engaged in the development of drugs for the treatment of neurodegenerative diseases including Alzheimer's disease, announced 14 million euros in series B funding led by Xerys.

BGF has provided an investment of £10m to CHS Healthcare, a leading national provider of specialist services for the NHS. The funding will be used to expand CHS’s infrastructure and operations, supporting the provision of services to the NHS nationwide.

BGF has made a significant minority investment in London Middlesex-based Revital, a multi-channel retailer of supplements, beauty and wellness products.

Backed by £9 million of investment capital from NVM Private Equity and a private US investor, Medovate is the first company dedicated to the development and commercialisation of innovative medical technologies from within the NHS, which will commercially benefit the NHS.